Why Is Universal Health Services (UHS) Up 12% Since Last Earnings Report?

Universal Health Services (UHS) has risen 12% since its last earnings report, outperforming the S&P 500, driven by upward estimate revisions and a strong VGM score of A. HCA Healthcare (HCA), a peer in the Medical-Hospital industry, has also gained 11.2% over the past month, reporting a 5.7% year-over-year revenue increase to $18.32 billion and EPS of $6.45, up from $5.36 a year ago; HCA is expected to post earnings of $6.20 per share for the current quarter, representing a year-over-year change of +12.7%.

Analysis

Universal Health Services (UHS) has demonstrated robust recent stock performance, appreciating approximately 12% since its last earnings report, thereby outperforming the S&P 500. This upward movement is primarily attributed to positive revisions in analyst estimates. The company currently boasts a strong aggregate VGM Score of A, underpinned by an A grade for both Growth and Value, although its Momentum Score is a slightly less robust B. Despite these encouraging indicators and the promising trend of upward estimate revisions, UHS maintains a Zacks Rank #3 (Hold), implying an expectation of in-line market returns over the next few months. Within the same Zacks Medical - Hospital industry, peer HCA Healthcare (HCA) has mirrored this positive trajectory, gaining 11.2% in the past month. HCA recently reported revenues of $18.32 billion for the quarter ended March 2025, a 5.7% year-over-year increase, and an EPS of $6.45, up from $5.36 in the prior year. For the current quarter, HCA is anticipated to report an EPS of $6.20, representing a 12.7% year-over-year growth, and similarly holds a Zacks Rank #3 (Hold) along with a VGM Score of A, suggesting a comparable neutral short-term outlook despite positive fundamental signals across the sector.

Key Decisions for Investors

• Investors should acknowledge Universal Health Services' recent 12% share price appreciation and positive estimate revisions, but temper expectations with the Zacks Rank #3 (Hold) which suggests in-line returns in the near term.
• While UHS exhibits strong Growth (A) and Value (A) scores, the B for Momentum warrants careful monitoring of share price trends and upcoming catalysts, such as the next earnings release, before significantly altering positions.
• The comparable positive performance and outlook for HCA Healthcare, including its 5.7% year-over-year revenue growth and anticipated 12.7% current quarter EPS growth, reinforce generally favorable conditions in the Medical - Hospital industry, yet the consistent Hold ratings for both key players suggest a balanced risk-reward profile currently.